Uroplasty (NASDAQ: UPI) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Uroplasty to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, dividends, risk and analyst recommendations.
This table compares Uroplasty and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of current recommendations and price targets for Uroplasty and its rivals, as provided by MarketBeat.com.
||Strong Buy Ratings
As a group, “Medical Devices & Implants” companies have a potential upside of 36.76%. Given Uroplasty’s rivals higher probable upside, analysts clearly believe Uroplasty has less favorable growth aspects than its rivals.
Risk and Volatility
Uroplasty has a beta of -1.26, suggesting that its share price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s rivals have a beta of 0.47, suggesting that their average share price is 53% less volatile than the S&P 500.
Institutional & Insider Ownership
54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 11.9% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Uroplasty and its rivals gross revenue, earnings per share and valuation.
Uroplasty’s rivals have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Uroplasty rivals beat Uroplasty on 6 of the 8 factors compared.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with MarketBeat.com's FREE daily email newsletter.